Business
TScan Therapeutics Announces Upcoming Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition
WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell
About this update from Tscan Therapeutics, Inc.
[{"type":"text","content":"WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that two abstracts related to its lead liquid tumor candidates TSC-100 and TSC-101 have been accepted for poster presentations at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 11-14, 2021. Abstracts are available on the ASH website at www.hematology.org. TSC-100 and TSC-101 are TCR-T cell products directed against the minor histocompatibility antigens HA-1 and HA-2, respectively, which are found only on blood cells. TScan is developing these products to prevent relapse following hematopoietic cell transplant (HCT) in myeloid leukemia. The Company plans to file investigational new drug applications (INDs) for both programs before the end of 2021. The current standard of care for the treatment of myeloid leukemia is HCT, which can provide a permanent cure but has a relapse rate of up to 50%, especially if the transplant uses reduced intensity conditioning (RIC), which is easier for patients to tolerate but typically does not completely eliminate their leukemia. TScan’s program is based on the well-established observation that patients who are mismatched with their donors for minor histocompatibility antigens such as HA-1 or HA-2, and naturally mount a T cell response against those antigens, show significantly lower relapse rates following HCT. By developing TSC-100 and TSC-101, TScan aims to recreate this natural graft versus leukemia response in order to prevent relapse in patients undergoing HCT. “We are excited to bring TSC-100 and TSC-101 to patients who are at risk of a devastating relapse after undergoing a demanding HCT,” said David Southwell, President and Chief Executive Officer of TScan Therapeutics. “We believe we are the only company that is advancing a T cell therapy product to safely reduce the risk of relapse, potentially addressing an important gap in the current leukemia treatment paradigm.” As described in its Nayar R. et al. abstract, TScan used its proprietary TCR discovery platform known as ReceptorScan to screen approximately 237 million CD8+ cells from five healthy HA-2-negative donors an...